Table 12.6i
Immunosuppression Use for Antirejection Treatment from Transplant to One Year Following Transplantation, 1995 to 2004
Recipients with Lung Transplants

	Year of Transplant									
	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004
Transplants	893	836	948	893	922	977	1,083	1,054	1,099	1,185
Tx with Antirejection Treatments	475	381	421	403	397	432	500	427	355	382
Antibodies										
Any in Category	9.5%	10.8%	11.6%	15.9%	16.1%	18.8%	11.4%	13.3%	16.1%	13.9%
Atgam/NRATG/NRATS	5.7%	7.3%	7.8%	10.9%	8.1%	7.4%	4.2%	3.0%	4.8%	4.2%
OKT3	4.2%	3.7%	4.3%	3.2%	3.0%	2.5%	1.4%	1.9%	0.8%	1.0%
Thymoglobulin	0.2%	0.0%	0.0%	0.7%	5.0%	5.8%	6.0%	4.9%	5.6%	6.8%
Zenapax	0.0%	0.0%	0.2%	2.2%	1.0%	3.0%	0.8%	5.2%	7.0%	1.8%
Simulect	0.0%	0.0%	0.0%	0.2%	0.8%	2.8%	0.6%	0.2%	0.6%	0.5%
Campath	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.5%	0.6%	0.5%
Corticosteroids										
Any in Category	93.7%	90.0%	94.1%	91.6%	92.9%	88.2%	92.4%	94.8%	96.3%	93.7%
Steroids	93.7%	90.0%	94.1%	91.6%	92.9%	88.2%	92.4%	94.8%	96.3%	93.7%
Antimetabolites										
Any in Category	1.1%	5.0%	1.9%	0.7%	1.5%	1.2%	1.2%	0.2%	1.4%	0.5%
Cytoxan	0.0%	0.8%	0.5%	0.2%	0.8%	0.5%	0.2%	0.2%	0.6%	0.5%
Methotrexate	1.1%	4.2%	1.4%	0.5%	1.5%	0.7%	1.0%	0.0%	0.8%	0.0%

Source: OPTN/SRTR Data as of May 1, 2006.
Notes:
Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.